Søren S Olesen1,2, Frederico G S Toledo3, Phil A Hart4. 1. Centre for Pancreatic Diseases, Department of Gastroenterology and Hepatology, Aalborg University Hospital. 2. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 3. Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Abstract
PURPOSE OF REVIEW: To discuss the spectrum of diabetes related to acute and chronic pancreatitis (which are types of pancreatogenic diabetes) and its overlapping features with type 1 and type 2 diabetes. RECENT FINDINGS: Patients with diabetes related to acute and chronic pancreatitis present clinically within a spectrum of overlapping features with other forms of diabetes. In this spectrum, glucose metabolism alterations range from increased insulin resistance following acute pancreatitis (resembling type 2 diabetes) towards a permanent loss of beta-cell function and impaired insulin secretion in end-stage chronic pancreatitis. Overlapping features with type 1 diabetes (beta cell autoantibodies) and type 2 diabetes (obesity, dyslipidemia, and hereditary/genetic factors) contribute to the heterogeneity of this spectrum. SUMMARY: Pancreatogenic diabetes secondary to acute or chronic pancreatitis is a heterogeneous entity with a variable clinical presentation, including many cases that are misdiagnosed and treated as type 2 diabetes. This is problematic as pancreatogenic diabetes is associated with a poor prognosis and entails special considerations for management. Recent discoveries showing overlapping features with type 1 and type 2 diabetes along with an improved understanding of its pathophysiology are expected to improve the diagnosis and treatment of these and other forms of pancreatogenic diabetes.
PURPOSE OF REVIEW: To discuss the spectrum of diabetes related to acute and chronic pancreatitis (which are types of pancreatogenic diabetes) and its overlapping features with type 1 and type 2 diabetes. RECENT FINDINGS: Patients with diabetes related to acute and chronic pancreatitis present clinically within a spectrum of overlapping features with other forms of diabetes. In this spectrum, glucose metabolism alterations range from increased insulin resistance following acute pancreatitis (resembling type 2 diabetes) towards a permanent loss of beta-cell function and impaired insulin secretion in end-stage chronic pancreatitis. Overlapping features with type 1 diabetes (beta cell autoantibodies) and type 2 diabetes (obesity, dyslipidemia, and hereditary/genetic factors) contribute to the heterogeneity of this spectrum. SUMMARY: Pancreatogenic diabetes secondary to acute or chronic pancreatitis is a heterogeneous entity with a variable clinical presentation, including many cases that are misdiagnosed and treated as type 2 diabetes. This is problematic as pancreatogenic diabetes is associated with a poor prognosis and entails special considerations for management. Recent discoveries showing overlapping features with type 1 and type 2 diabetes along with an improved understanding of its pathophysiology are expected to improve the diagnosis and treatment of these and other forms of pancreatogenic diabetes.
Authors: Marcus Lind; William Polonsky; Irl B Hirsch; Tim Heise; Jan Bolinder; Sofia Dahlqvist; Erik Schwarz; Arndís Finna Ólafsdóttir; Anders Frid; Hans Wedel; Elsa Ahlén; Thomas Nyström; Jarl Hellman Journal: JAMA Date: 2017-01-24 Impact factor: 56.272
Authors: Chris Woodmansey; Andrew P McGovern; Katherine A McCullough; Martin B Whyte; Neil M Munro; Ana C Correa; Piers A C Gatenby; Simon A Jones; Simon de Lusignan Journal: Diabetes Care Date: 2017-08-31 Impact factor: 19.112
Authors: Søren S Olesen; Jakob L Poulsen; Srdan Novovic; Camilla Nøjgaard; Evangelos Kalaitzakis; Nanna M Jensen; Trond Engjom; Erling Tjora; Anne Waage; Truls Hauge; Stephan L Haas; Miroslav Vujasinovic; Giedrius Barauskas; Aldis Pukitis; Imanta Ozola-Zālīte; Alexey Okhlobystin; Mikael Parhiala; Johanna Laukkarinen; Asbjørn M Drewes Journal: United European Gastroenterol J Date: 2020-01-17 Impact factor: 4.623
Authors: Qiong Wei; Liang Qi; Hao Lin; Dechen Liu; Xiangyun Zhu; Yu Dai; Richard T Waldron; Aurelia Lugea; Mark O Goodarzi; Stephen J Pandol; Ling Li Journal: Front Physiol Date: 2020-10-28 Impact factor: 4.566